cagrilintide semaglutide combination phase 3 2024 Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, study Efficacy and safety of co-administered

If you have concerns about taking Rybelsus and omeprazole together, discuss these with your GP or diabetes specialist nurse to ensure your treatment plan is optimised

Not for human or veterinary consumption

Works well for most adults with average to above-average subcutaneous fat

However, this approach works best as part of a comprehensive strategy that includes a balanced diet, regular exercise, and medical supervision

Semaglutide is still under patent protection by Novo Nordisk

The STEP (Semaglutide Treatment Effect in People with obesity) trial program showed average weight reductions of approximately 15% of initial body weight over 68 weeks in individuals without diabetes, with somewhat lower reductions (about 9-10%) in those with type 2 diabetes